By Fineline Cube 
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across China. This milestone marks the drug’s official entry into the Chinese market following its conditional approval in March of this year.
Drug Background
Tazverik, an EZH2 methyltransferase inhibitor developed by Ipsen’s unit Epizyme, Inc., received accelerated approval in the US in January and June of 2020 for the treatment of advanced epithelioid sarcoma and relapsed or refractory (R/R) follicular lymphoma (FL). The drug also gained marketing approval in Japan.
Licensing and Commercialization
HutchMed entered into a licensing agreement with Ipsen in 2021, acquiring rights for research and development, manufacturing, and commercialization of Tazverik in Mainland China, Hong Kong, Macau, and Taiwan. The drug’s conditional marketing approval in China is specifically for the treatment of R/R FL with EZH2 mutations in patients who have previously received at least two systemic therapies.-Fineline Info & Tech